Driehaus Capital Management LLC Invests $2.01 Million in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Driehaus Capital Management LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 594,015 shares of the company's stock, valued at approximately $2,014,000. Driehaus Capital Management LLC owned about 0.40% of Xeris Biopharma as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. NewEdge Advisors LLC bought a new stake in Xeris Biopharma in the fourth quarter worth $34,000. R Squared Ltd purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at $42,000. Cibc World Markets Corp purchased a new position in Xeris Biopharma in the fourth quarter valued at about $44,000. Raymond James Financial Inc. bought a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $45,000. Finally, Aquatic Capital Management LLC bought a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $50,000. 42.75% of the stock is currently owned by institutional investors.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.47% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on XERS shares. Jefferies Financial Group restated a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler reissued a "neutral" rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners boosted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Stock Up 4.2%

NASDAQ XERS traded up $0.20 during trading on Thursday, hitting $4.84. The stock had a trading volume of 1,016,983 shares, compared to its average volume of 1,936,966. The firm has a 50 day moving average price of $4.71 and a 200 day moving average price of $3.88. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.86 and a twelve month high of $6.07. The company has a market capitalization of $756.12 million, a PE ratio of -10.77 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to analysts' expectations of $57.61 million. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.